Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for FMR LLC / Fidelity Management & Research. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at FMR LLC / Fidelity Management & Research har rapporteret besiddelser eller handler i følgende virksomheder:
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af FMR LLC / Fidelity Management & Research. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb ACRS / Aclaris Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2015-10-13 | ACRS | FMR LLC / Fidelity Management & Research | 335.455 | 11,0000 | 335.455 | 11,0000 | 3.690.005 | 70 | 29.28 | 6.132.117 | 166,18 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ACRS / Aclaris Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb BEAM / Beam Therapeutics Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg BEAM / Beam Therapeutics Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb CHRS / Coherus Oncology, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CHRS / Coherus Oncology, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb COGT / Cogent Biosciences, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2018-04-03 | UMRX | FMR LLC / Fidelity Management & Research | 94.052 | 12,0000 | 23.513 | 48,0000 | 1.128.624 | 119 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg COGT / Cogent Biosciences, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb CRBU / Caribou Biosciences, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CRBU / Caribou Biosciences, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb DTIL / Precision BioSciences, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2019-04-01 | DTIL | FMR LLC / Fidelity Management & Research | 50.000 | 16,0000 | 1.667 | 480,0000 | 800.000 | 249 | 19.66 | -767.246 | -95,91 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg DTIL / Precision BioSciences, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb FLYW / Flywire Corporation – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg FLYW / Flywire Corporation – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb GNRC / Generac Holdings Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2014-07-01 | GNRC | FMR LLC / Fidelity Management & Research | 27.168 | 47,0400 | 27.168 | 47,0400 | 1.277.983 | 237 | 50.4100 | 91.557 | 7,16 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg GNRC / Generac Holdings Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb INSM / Insmed Incorporated – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg INSM / Insmed Incorporated – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb IRWD / Ironwood Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg IRWD / Ironwood Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb MRSN / Mersana Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg MRSN / Mersana Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb NMRA / Neumora Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg NMRA / Neumora Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RGNX / REGENXBIO Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RGNX / REGENXBIO Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RLYB / Rallybio Corporation – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RLYB / Rallybio Corporation – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SANA / Sana Biotechnology, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SANA / Sana Biotechnology, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb VRAYQ / ViewRay, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg VRAYQ / ViewRay, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb VYNE / VYNE Therapeutics Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg VYNE / VYNE Therapeutics Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb XLO / Xilio Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg XLO / Xilio Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af FMR LLC / Fidelity Management & Research som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-09-12 |
|
4/A | MTSR |
Metsera, Inc.
Common Stock |
J - Other | 1.107.547 | 1.107.547 | |||||
2025-09-04 |
|
4 | MTSR |
Metsera, Inc.
Common Stock |
J - Other | 1.134.258 | 1.134.258 | |||||
2025-09-04 |
|
4 | MTSR |
Metsera, Inc.
Common Stock |
S - Sale | -268 | 0 | -100,00 | 36,00 | -9.648 | ||
2025-09-04 |
|
4 | MTSR |
Metsera, Inc.
Common Stock |
J - Other | -997.044 | 268 | -99,97 | ||||
2025-09-04 |
|
4 | MTSR |
Metsera, Inc.
Common Stock |
J - Other | 997.312 | 997.312 | |||||
2025-09-04 |
|
4 | MTSR |
Metsera, Inc.
Common Shares |
J - Other | 895 | 895 | |||||
2025-09-04 |
|
4 | MTSR |
Metsera, Inc.
Common Stock |
J - Other | -20.250 | 0 | -100,00 | ||||
2025-09-04 |
|
4 | MTSR |
Metsera, Inc.
Common Stock |
J - Other | 20.250 | 20.250 | |||||
2025-09-04 |
|
4 | MTSR |
Metsera, Inc.
Common Stock |
J - Other | -1.350.000 | 3.189.540 | -29,74 | ||||
2025-08-01 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
S - Sale | -48.374 | 2.073.665 | -2,28 | 20,50 | -991.667 | 42.510.132 | |
2025-04-10 | 3 | BEAM |
Beam Therapeutics Inc.
Common Stock |
1.139.443 | ||||||||
2025-04-10 | 3 | BEAM |
Beam Therapeutics Inc.
Common Stock |
473 | ||||||||
2025-04-10 | 3 | BEAM |
Beam Therapeutics Inc.
Common Stock |
2.122.039 | ||||||||
2025-02-05 |
|
4 | MTSR |
Metsera, Inc.
Common Stock |
C - Conversion | 3.120.934 | 4.539.540 | 220,00 | ||||
2025-02-05 |
|
4 | MTSR |
Metsera, Inc.
Common Stock |
C - Conversion | 1.418.606 | 1.418.606 | |||||
2025-01-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -1.000 | 4.541.511 | -0,02 | 7,26 | -7.260 | 32.971.370 | |
2025-01-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -164.912 | 4.542.511 | -3,50 | 6,71 | -1.106.560 | 30.480.249 | |
2025-01-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -25.000 | 4.707.423 | -0,53 | 6,50 | -162.500 | 30.598.250 | |
2025-01-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -100.000 | 4.732.423 | -2,07 | 6,11 | -611.000 | 28.915.105 | |
2024-11-21 | 3/A | SANA |
Sana Biotechnology, Inc.
Common Stock |
61 | ||||||||
2024-09-18 |
|
4 | BCAX |
Bicara Therapeutics Inc.
Common Stock |
C - Conversion | 392.085 | 1.115.333 | 54,21 | ||||
2024-09-18 |
|
4 | BCAX |
Bicara Therapeutics Inc.
Common Stock |
C - Conversion | 712.430 | 723.248 | 6.585,60 | ||||
2024-09-18 |
|
4 | BCAX |
Bicara Therapeutics Inc.
Common Stock |
C - Conversion | 10.818 | 10.818 | |||||
2024-06-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares |
45.120 | ||||||||
2024-06-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares |
530.814 | ||||||||
2024-04-08 | 3 | SANA |
Sana Biotechnology, Inc.
Common Stock |
4.832.423 | ||||||||
2024-02-15 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
S - Sale | -45.677 | 1.235.511 | -3,57 | 31,34 | -1.431.517 | 38.720.915 | |
2024-02-15 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
S - Sale | -854.323 | 1.281.188 | -40,01 | 30,51 | -26.065.395 | 39.089.046 | |
2024-02-15 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
S - Sale | -1.155 | 2.771.913 | -0,04 | 30,93 | -35.724 | 85.735.269 | |
2024-02-15 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
S - Sale | -410 | 2.773.068 | -0,01 | 30,28 | -12.415 | 83.968.499 | |
2023-12-27 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -29.549 | 2.773.478 | -1,05 | ||||
2023-11-29 |
|
4 | NONE |
Fidelity Private Credit Fund
Class D Common Shares of Beneficial Interest |
P - Purchase | 391 | 391 | 25,54 | 9.999 | 9.999 | ||
2023-11-29 |
|
4 | NONE |
Fidelity Private Credit Fund
Class S Common Shares of Beneficial Interest |
P - Purchase | 391 | 391 | 25,54 | 9.999 | 9.999 | ||
2023-10-12 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares |
61.527 | ||||||||
2023-10-12 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares |
723.837 | ||||||||
2023-09-21 |
|
4 | NMRA |
Neumora Therapeutics, Inc.
Common Stock |
C - Conversion | 88.289 | 88.289 | |||||
2023-09-21 |
|
4 | NMRA |
Neumora Therapeutics, Inc.
Common Stock |
C - Conversion | 63.724 | 63.724 | |||||
2023-09-21 |
|
4 | NMRA |
Neumora Therapeutics, Inc.
Common Stock |
C - Conversion | 84.965 | 5.472.340 | 1,58 | ||||
2023-09-21 |
|
4 | NMRA |
Neumora Therapeutics, Inc.
Common Stock |
C - Conversion | 3.475.646 | 5.387.375 | 181,81 | ||||
2023-09-14 | 3 | NMRA |
Neumora Therapeutics, Inc.
Common Stock |
1.911.729 | ||||||||
2023-07-27 |
|
4 | TSBX |
Turnstone Biologics Corp.
Common Stock |
C - Conversion | 4.939 | 4.939 | |||||
2023-07-27 |
|
4 | TSBX |
Turnstone Biologics Corp.
Common Stock |
C - Conversion | 296.396 | 296.396 | |||||
2023-07-27 |
|
4 | TSBX |
Turnstone Biologics Corp.
Common Stock |
C - Conversion | 483.684 | 832.652 | 138,60 | ||||
2023-07-27 |
|
4 | TSBX |
Turnstone Biologics Corp.
Common Stock |
C - Conversion | 150.809 | 348.968 | 76,11 | ||||
2023-07-27 |
|
4 | TSBX |
Turnstone Biologics Corp.
Common Stock |
C - Conversion | 106.496 | 198.159 | 116,18 | ||||
2023-07-27 |
|
4 | TSBX |
Turnstone Biologics Corp.
Common Stock |
C - Conversion | 91.663 | 91.663 | |||||
2023-06-29 |
|
4 | NONE |
Fidelity Private Credit Fund
Class I Common Shares of Beneficial Interest |
P - Purchase | 346.723 | 346.723 | 25,23 | 8.747.816 | 8.747.816 | ||
2023-05-26 | 3 | NONE |
Fidelity Multi-Strategy Credit Fund
Common Shares of Beneficial Ownership |
2.500.000 | ||||||||
2023-03-23 | 3 | NONE |
Fidelity Private Credit Fund
Class I Common Shares of Beneficial Interest |
1.280.002 | ||||||||
2023-03-23 | 3 | NONE |
Fidelity Private Credit Fund
Class I Common Shares of Beneficial Interest |
80 | ||||||||
2023-02-09 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares |
C - Conversion | 214.663 | 4.769.404 | 4,71 | ||||
2023-02-09 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares |
C - Conversion | 414.621 | 4.554.741 | 10,01 | ||||
2023-02-09 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares |
C - Conversion | 568.098 | 4.140.120 | 15,90 | ||||
2023-02-09 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares |
C - Conversion | 3.572.022 | 3.572.022 | |||||
2023-02-09 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares |
C - Conversion | 6.947 | 82.035 | 9,25 | ||||
2023-02-09 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares |
C - Conversion | 7.411 | 75.088 | 10,95 | ||||
2023-02-09 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares |
C - Conversion | 10.154 | 67.677 | 17,65 | ||||
2023-02-09 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares |
C - Conversion | 57.523 | 57.523 | |||||
2023-02-09 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares |
C - Conversion | 965.115 | 965.115 | |||||
2022-10-26 |
|
4 | PRME |
Prime Medicine, Inc.
Common Stock |
C - Conversion | 423.509 | 4.228.589 | 11,13 | ||||
2022-10-26 |
|
4 | PRME |
Prime Medicine, Inc.
Common Stock |
C - Conversion | 3.805.080 | 3.805.080 | |||||
2022-10-26 |
|
4 | PRME |
Prime Medicine, Inc.
Common Stock |
C - Conversion | 11.015 | 109.982 | 11,13 | ||||
2022-10-26 |
|
4 | PRME |
Prime Medicine, Inc.
Common Stock |
C - Conversion | 98.967 | 98.967 | |||||
2022-10-26 |
|
4 | PRME |
Prime Medicine, Inc.
Common Stock |
C - Conversion | 4.124.375 | 4.124.375 | |||||
2022-09-08 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
S - Sale | -551 | 0 | -100,00 | 54,25 | -29.892 | ||
2022-09-08 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 551 | 551 | |||||
2022-09-08 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -25.620 | 0 | -100,00 | ||||
2022-08-08 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
S - Sale | -20.159 | 0 | -100,00 | 60,50 | -1.219.620 | ||
2022-08-08 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
S - Sale | -167 | 0 | -100,00 | 61,00 | -10.187 | ||
2022-08-08 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 312.512 | 2.803.027 | 12,55 | ||||
2022-08-08 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 20.159 | 20.159 | |||||
2022-08-08 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -167.564 | 25.620 | -86,74 | ||||
2022-08-08 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 180.366 | 193.184 | 1.407,13 | ||||
2022-08-08 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -375.369 | 167 | -99,96 | ||||
2022-08-08 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 375.536 | 375.536 | |||||
2022-08-08 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -800.000 | 2.135.511 | -27,25 | ||||
2022-07-14 |
|
4 | VERV |
Verve Therapeutics, Inc.
Common Stock |
S - Sale | -63.000 | 570.729 | -9,94 | 22,04 | -1.388.520 | 12.578.867 | |
2022-07-14 |
|
4 | VERV |
Verve Therapeutics, Inc.
Common Stock |
S - Sale | -100.000 | 633.729 | -13,63 | 19,98 | -1.998.000 | 12.661.905 | |
2022-07-06 |
|
4 | VERV |
Verve Therapeutics, Inc.
Common Stock |
S - Sale | -38.775 | 773.729 | -4,77 | 15,66 | -607.216 | 12.116.596 | |
2022-07-01 |
|
4 | VERV |
Verve Therapeutics, Inc.
Common Stock |
S - Sale | -18.810 | 772.504 | -2,38 | 15,21 | -286.100 | 11.749.786 | |
2022-07-01 |
|
4 | VERV |
Verve Therapeutics, Inc.
Common Stock |
S - Sale | -30.362 | 791.314 | -3,70 | 15,60 | -473.647 | 12.344.498 | |
2022-07-01 |
|
4 | VERV |
Verve Therapeutics, Inc.
Common Stock |
S - Sale | -4.047 | 821.676 | -0,49 | 15,50 | -62.728 | 12.735.978 | |
2022-04-14 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
S - Sale | -3.200 | 0 | -100,00 | 50,80 | -162.560 | ||
2022-04-14 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
S - Sale | -8.804 | 3.200 | -73,34 | 50,01 | -440.288 | 160.032 | |
2022-04-14 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
S - Sale | -6.799 | 12.004 | -36,16 | 50,70 | -344.709 | 608.603 | |
2022-04-14 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
S - Sale | -663 | 0 | -100,00 | 50,75 | -33.647 | ||
2022-04-14 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 422.120 | 2.490.515 | 20,41 | ||||
2022-04-14 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 15.406 | 18.803 | 453,52 | ||||
2022-04-14 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -128.333 | 12.818 | -90,92 | ||||
2022-04-14 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 137.845 | 141.151 | 4.169,54 | ||||
2022-04-14 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -509.332 | 663 | -99,87 | ||||
2022-04-14 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 509.490 | 509.995 | 100.889,11 | ||||
2022-04-14 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -978.503 | 2.935.511 | -25,00 | ||||
2022-03-11 |
|
4 | VERV |
Verve Therapeutics, Inc.
Common Stock |
S - Sale | -3.971 | 825.723 | -0,48 | 29,01 | -115.199 | 23.954.224 | |
2022-02-11 |
|
4 | VERV |
Verve Therapeutics, Inc.
Common Stock |
S - Sale | -13.190 | 829.694 | -1,56 | 29,46 | -388.577 | 24.442.785 | |
2022-02-03 |
|
4 | VERV |
Verve Therapeutics, Inc.
Common Stock |
S - Sale | -35.574 | 842.884 | -4,05 | 29,04 | -1.033.069 | 24.477.351 | |
2022-01-28 |
|
4 | VERV |
Verve Therapeutics, Inc.
Common Stock |
S - Sale | -247 | 878.458 | -0,03 | 30,02 | -7.415 | 26.371.309 | |
2022-01-28 |
|
4 | VERV |
Verve Therapeutics, Inc.
Common Stock |
S - Sale | -8.736 | 878.705 | -0,98 | 29,26 | -255.615 | 25.710.908 | |
2022-01-28 |
|
4 | VERV |
Verve Therapeutics, Inc.
Common Stock |
S - Sale | -45.946 | 887.441 | -4,92 | 31,96 | -1.468.434 | 28.362.614 | |
2022-01-28 |
|
4 | VERV |
Verve Therapeutics, Inc.
Common Stock |
S - Sale | -88.989 | 933.387 | -8,70 | 31,12 | -2.769.338 | 29.047.003 | |
2022-01-28 |
|
4 | VERV |
Verve Therapeutics, Inc.
Common Stock |
S - Sale | -14.918 | 1.022.376 | -1,44 | 29,67 | -442.617 | 30.333.896 | |
2022-01-24 | 3 | BEAM |
Beam Therapeutics Inc.
Common Stock |
3.914.014 | ||||||||
2022-01-24 | 3 | BEAM |
Beam Therapeutics Inc.
Common Stock |
3.306 | ||||||||
2022-01-24 | 3 | BEAM |
Beam Therapeutics Inc.
Common Stock |
3.397 | ||||||||
2022-01-24 | 3 | BEAM |
Beam Therapeutics Inc.
Common Stock |
505 | ||||||||
2022-01-24 | 3 | BEAM |
Beam Therapeutics Inc.
Common Stock |
2.068.395 | ||||||||
2021-12-28 | 3 | VERV |
Verve Therapeutics, Inc.
Common Stock |
1.037.294 | ||||||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -42.421 | 0 | -100,00 | ||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -3.536.046 | 0 | -100,00 | ||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -272.687 | 0 | -100,00 | ||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Series A-1 Preferred Stock |
C - Conversion | -6.521.739 | 0 | -100,00 | ||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -7.500.000 | 0 | -100,00 | ||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Common Stock |
C - Conversion | 4.465 | 4.465 | |||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Common Stock |
C - Conversion | 372.215 | 372.215 | |||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Common Stock |
C - Conversion | 28.703 | 1.530.990 | 1,91 | ||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Common Stock |
C - Conversion | 686.499 | 1.502.287 | 84,15 | ||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Common Stock |
C - Conversion | 789.473 | 815.788 | 3.000,09 | ||||
2021-10-21 | 3 | XLO |
Xilio Therapeutics, Inc.
Common Stock |
26.315 | ||||||||
2021-08-26 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 793.736 | 1.744.221 | 83,51 | ||||
2021-08-26 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -969.038 | 304 | -99,97 | ||||
2021-08-26 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 969.189 | 969.342 | 633.456,86 | ||||
2021-08-26 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 1.569 | 2.293 | 216,71 | ||||
2021-08-26 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -16.153 | 0 | -100,00 | ||||
2021-08-26 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 16.153 | 16.153 | |||||
2021-08-26 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -1.615.314 | 4.611.205 | -25,94 | ||||
2021-08-16 |
|
4/A | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 950.485 | 950.485 | |||||
2021-08-16 |
|
4/A | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -1.160.430 | 153 | -99,99 | ||||
2021-08-16 |
|
4/A | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 447.236 | 1.160.583 | 62,70 | ||||
2021-08-16 |
|
4/A | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 724 | 724 | |||||
2021-08-16 |
|
4/A | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -7.454 | 0 | -100,00 | ||||
2021-08-16 |
|
4/A | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 7.454 | 7.454 | |||||
2021-08-16 |
|
4/A | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -745.393 | 6.226.519 | -10,69 | ||||
2021-08-10 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -1.160.430 | 153 | -99,99 | ||||
2021-08-10 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 447.236 | 1.160.583 | 62,70 | ||||
2021-08-10 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 724 | 724 | |||||
2021-08-10 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -7.454 | 0 | -100,00 | ||||
2021-08-10 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 7.454 | 7.454 | |||||
2021-08-10 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | -745.393 | 6.226.519 | -10,69 | ||||
2021-08-04 |
|
4 | RLYB |
Rallybio Corp
Series B Preferred Units |
C - Conversion | -10.789.193 | 0 | -100,00 | ||||
2021-08-04 |
|
4 | RLYB |
Rallybio Corp
Common Stock |
C - Conversion | 1.694.388 | 1.694.388 | |||||
2021-07-29 |
|
4 | CRBU |
Caribou Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -805.707 | 0 | -100,00 | ||||
2021-07-29 |
|
4 | CRBU |
Caribou Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -9.666 | 0 | -100,00 | ||||
2021-07-29 |
|
4 | CRBU |
Caribou Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -588.794 | 0 | -100,00 | ||||
2021-07-29 |
|
4 | CRBU |
Caribou Biosciences, Inc.
Series B Preferred Stock |
C - Conversion | -423.823 | 0 | -100,00 | ||||
2021-07-29 |
|
4 | CRBU |
Caribou Biosciences, Inc.
Common Stock |
C - Conversion | 1.464.775 | 1.464.775 | |||||
2021-07-29 |
|
4 | CRBU |
Caribou Biosciences, Inc.
Common Stock |
C - Conversion | 17.572 | 17.572 | |||||
2021-07-29 |
|
4 | CRBU |
Caribou Biosciences, Inc.
Common Stock |
C - Conversion | 1.070.427 | 1.840.937 | 138,92 | ||||
2021-07-29 |
|
4 | CRBU |
Caribou Biosciences, Inc.
Common Stock |
C - Conversion | 770.510 | 770.510 | |||||
2021-06-23 |
|
4 | VERV |
Verve Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -8.361.204 | 0 | -100,00 | ||||
2021-06-23 |
|
4 | VERV |
Verve Therapeutics, Inc.
Series A-2 Preferred Stock |
C - Conversion | -1.243.626 | 0 | -100,00 | ||||
2021-06-23 |
|
4 | VERV |
Verve Therapeutics, Inc.
Common Stock |
C - Conversion | 902.986 | 1.037.294 | 672,32 | ||||
2021-06-23 |
|
4 | VERV |
Verve Therapeutics, Inc.
Common Stock |
C - Conversion | 134.308 | 134.308 | |||||
2021-06-02 |
|
4 | FLYW |
Flywire Corp
Series A Preferred Stock |
C - Conversion | -19.434 | 0 | -100,00 | ||||
2021-06-02 |
|
4 | FLYW |
Flywire Corp
Series B Preferred Stock |
C - Conversion | -420.024 | 0 | -100,00 | ||||
2021-06-02 |
|
4 | FLYW |
Flywire Corp
Series C Preferred Stock |
C - Conversion | -1.500.435 | 0 | -100,00 | ||||
2021-06-02 |
|
4 | FLYW |
Flywire Corp
Series B-1 NV Preferred Stock |
C - Conversion | -1.145.526 | 0 | -100,00 | ||||
2021-06-02 |
|
4 | FLYW |
Flywire Corp
Series B-1 Preferred Stock |
C - Conversion | -4.183.071 | 0 | -100,00 | ||||
2021-06-02 |
|
4 | FLYW |
Flywire Corp
Common Stock |
C - Conversion | 19.434 | 7.268.490 | 0,27 | ||||
2021-06-02 |
|
4 | FLYW |
Flywire Corp
Common Stock |
C - Conversion | 420.024 | 7.249.056 | 6,15 | ||||
2021-06-02 |
|
4 | FLYW |
Flywire Corp
Common Stock |
C - Conversion | 1.500.435 | 6.829.032 | 28,16 | ||||
2021-06-02 |
|
4 | FLYW |
Flywire Corp
Common Stock |
C - Conversion | 1.145.526 | 5.328.597 | 27,38 | ||||
2021-06-02 |
|
4 | FLYW |
Flywire Corp
Common Stock |
C - Conversion | 4.183.071 | 4.183.071 | |||||
2021-05-26 | 3 | FLYW |
Flywire Corp
Common Stock |
191.838 | ||||||||
2021-02-23 |
|
4 | ORTX |
Orchard Therapeutics plc
American Depository Shares |
C - Conversion | 409.852 | 1.000.000 | 69,45 | ||||
2021-02-23 |
|
4 | ORTX |
Orchard Therapeutics plc
American Depository Shares |
C - Conversion | 409.852 | 1.000.000 | 69,45 | ||||
2021-02-23 |
|
4 | ORTX |
Orchard Therapeutics plc
Ordinary shares |
C - Conversion | -409.852 | 4.099.540 | -9,09 | ||||
2021-02-23 |
|
4 | ORTX |
Orchard Therapeutics plc
Ordinary shares |
C - Conversion | -409.852 | 4.099.540 | -9,09 | ||||
2021-02-10 |
|
4 | ORTX |
Orchard Therapeutics plc
Ordinary shares |
S - Sale | -1.022.755 | 5.099.540 | -16,71 | 6,98 | -7.138.830 | 35.594.789 | |
2021-02-10 |
|
4 | ORTX |
Orchard Therapeutics plc
Ordinary shares |
S - Sale | -1.022.755 | 5.099.540 | -16,71 | 6,98 | -7.138.830 | 35.594.789 | |
2021-02-01 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 356.673 | 713.347 | 100,00 | ||||
2020-08-11 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
J - Other | 356.674 | 356.674 | |||||
2020-02-12 |
|
4 | BEAM |
Beam Therapeutics Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -9.819.820 | 0 | -100,00 | ||||
2020-02-12 |
|
4 | BEAM |
Beam Therapeutics Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -21.146.743 | 0 | -100,00 | ||||
2020-02-12 |
|
4 | BEAM |
Beam Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -297.620 | 0 | -100,00 | ||||
2020-02-12 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
C - Conversion | 2.189.820 | 6.971.912 | 45,79 | ||||
2020-02-12 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
C - Conversion | 4.715.723 | 4.782.092 | 7.105,31 | ||||
2020-02-12 |
|
4 | BEAM |
Beam Therapeutics Inc.
Common Stock |
C - Conversion | 66.369 | 66.369 | |||||
2020-01-06 |
|
4 | ORTX |
Orchard Therapeutics plc
Ordinary Shares |
S - Sale | 8.753 | 6.122.295 | 0,14 | 13,41 | 117.378 | 82.099.976 | |
2020-01-06 |
|
4 | ORTX |
Orchard Therapeutics plc
Ordinary Shares |
S - Sale | -5.484 | 6.131.048 | -0,09 | 13,55 | -74.308 | 83.075.700 | |
2020-01-06 |
|
4 | ORTX |
Orchard Therapeutics plc
Ordinary Shares |
S - Sale | -5.484 | 6.131.048 | -0,09 | 13,55 | -74.308 | 83.075.700 | |
2020-01-06 |
|
4 | ORTX |
Orchard Therapeutics plc
Ordinary Shares |
S - Sale | -8.753 | 6.122.295 | -0,14 | 13,41 | -117.378 | 82.099.976 | |
2020-01-02 | 3 | ORTX |
Orchard Therapeutics plc
Ordinary shares |
18.409.596 | ||||||||
2020-01-02 | 3 | ORTX |
Orchard Therapeutics plc
Ordinary shares |
18.409.596 | ||||||||
2020-01-02 | 3 | ORTX |
Orchard Therapeutics plc
Ordinary shares |
18.409.596 | ||||||||
2020-01-02 | 3 | ORTX |
Orchard Therapeutics plc
Ordinary shares |
18.409.596 | ||||||||
2020-01-02 | 3 | ORTX |
Orchard Therapeutics plc
Ordinary shares |
18.409.596 | ||||||||
2020-01-02 | 3 | ORTX |
Orchard Therapeutics plc
Ordinary shares |
18.409.596 | ||||||||
2019-04-03 |
|
4 | DTIL |
PRECISION BIOSCIENCES INC
Series B Preferred Stock |
C - Conversion | -873.253 | 0 | -100,00 | ||||
2019-04-03 |
|
4 | DTIL |
PRECISION BIOSCIENCES INC
Series A Preferred Stock |
C - Conversion | -7.000.000 | 0 | -100,00 | ||||
2019-04-03 |
|
4 | DTIL |
PRECISION BIOSCIENCES INC
Common Stock |
P - Purchase | 50.000 | 3.738.248 | 1,36 | 16,00 | 800.000 | 59.811.968 | |
2019-04-03 |
|
4 | DTIL |
PRECISION BIOSCIENCES INC
Common Stock |
C - Conversion | 409.078 | 3.688.248 | 12,48 | ||||
2019-04-03 |
|
4 | DTIL |
PRECISION BIOSCIENCES INC
Common Stock |
C - Conversion | 3.279.170 | 3.279.170 | |||||
2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -200.000 | 604.736 | -24,85 | 10,02 | -2.004.000 | 6.059.455 | |
2018-08-08 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -4.200 | 804.736 | -0,52 | 10,16 | -42.672 | 8.176.118 | |
2018-08-08 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -11.400 | 808.936 | -1,39 | 10,12 | -115.368 | 8.186.432 | |
2018-08-08 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -10.000 | 820.336 | -1,20 | 10,10 | -101.000 | 8.285.394 | |
2018-08-08 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.000 | 830.336 | -0,12 | 10,38 | -10.380 | 8.618.888 | |
2018-08-08 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -7.200 | 831.336 | -0,86 | 10,69 | -76.968 | 8.886.982 | |
2018-08-08 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -2.980 | 838.536 | -0,35 | 10,77 | -32.095 | 9.031.033 | |
2018-08-08 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -6.900 | 841.516 | -0,81 | 10,68 | -73.692 | 8.987.391 | |
2018-08-08 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -2.000 | 848.416 | -0,24 | 10,48 | -20.960 | 8.891.400 | |
2018-08-08 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -58.280 | 850.416 | -6,41 | 10,45 | -609.026 | 8.886.847 | |
2018-08-08 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -2.879 | 908.696 | -0,32 | 10,56 | -30.402 | 9.595.830 | |
2018-08-08 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -24.367 | 911.575 | -2,60 | 10,64 | -259.265 | 9.699.158 | |
2018-08-08 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -10.673 | 935.942 | -1,13 | 10,47 | -111.746 | 9.799.313 | |
2018-08-08 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -19.550 | 946.615 | -2,02 | 10,59 | -207.034 | 10.024.653 | |
2018-08-08 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -5.700 | 966.165 | -0,59 | 10,68 | -60.876 | 10.318.642 | |
2018-08-08 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -400 | 971.865 | -0,04 | 10,69 | -4.276 | 10.389.237 | |
2018-08-08 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -6.400 | 972.265 | -0,65 | 10,48 | -67.072 | 10.189.337 | |
2018-08-06 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -30.000 | 978.665 | -2,97 | 11,46 | -343.800 | 11.215.501 | |
2018-08-06 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -225.153 | 1.008.665 | -18,25 | 11,25 | -2.532.971 | 11.347.481 | |
2018-08-06 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -2.587 | 1.233.818 | -0,21 | 12,00 | -31.044 | 14.805.816 | |
2018-08-06 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -12.035 | 1.236.405 | -0,96 | 12,16 | -146.346 | 15.034.685 | |
2018-08-06 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -64.900 | 1.248.440 | -4,94 | 11,95 | -775.555 | 14.918.858 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -7.600 | 1.313.340 | -0,58 | 11,91 | -90.516 | 15.641.879 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -3.200 | 1.320.940 | -0,24 | 11,94 | -38.208 | 15.772.024 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -778 | 1.324.140 | -0,06 | 11,95 | -9.297 | 15.823.473 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.200 | 1.324.918 | -0,09 | 11,95 | -14.340 | 15.832.770 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -8.600 | 1.326.118 | -0,64 | 11,93 | -102.598 | 15.820.588 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -2.900 | 1.334.718 | -0,22 | 12,02 | -34.858 | 16.043.310 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.000 | 1.337.618 | -0,07 | 12,18 | -12.180 | 16.292.187 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -800 | 1.338.618 | -0,06 | 12,10 | -9.680 | 16.197.278 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -3.000 | 1.339.418 | -0,22 | 12,13 | -36.390 | 16.247.140 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.500 | 1.342.418 | -0,11 | 11,95 | -17.925 | 16.041.895 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -35.756 | 1.343.918 | -2,59 | 12,11 | -433.005 | 16.274.847 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.000 | 1.379.674 | -0,07 | 12,03 | -12.030 | 16.597.478 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -500 | 1.380.674 | -0,04 | 12,13 | -6.065 | 16.747.576 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -6.522 | 1.381.174 | -0,47 | 12,11 | -78.981 | 16.726.017 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -900 | 1.387.696 | -0,06 | 12,11 | -10.899 | 16.804.999 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -30.000 | 1.388.596 | -2,11 | 12,12 | -363.600 | 16.829.784 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -2.700 | 1.418.596 | -0,19 | 12,13 | -32.751 | 17.207.569 | |
2018-08-02 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -19.250 | 1.421.296 | -1,34 | 12,07 | -232.348 | 17.155.043 | |
2018-07-31 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -10.000 | 1.440.546 | -0,69 | 11,44 | -114.400 | 16.479.846 | |
2018-07-31 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -11.500 | 1.450.546 | -0,79 | 11,39 | -130.985 | 16.521.719 | |
2018-07-31 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -68.092 | 1.462.046 | -4,45 | 11,36 | -773.525 | 16.608.843 | |
2018-07-31 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -253 | 1.530.138 | -0,02 | 11,36 | -2.874 | 17.382.368 | |
2018-07-31 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -600 | 1.530.391 | -0,04 | 11,52 | -6.912 | 17.630.104 | |
2018-07-31 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.200 | 1.530.991 | -0,08 | 11,54 | -13.848 | 17.667.636 | |
2018-07-31 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.600 | 1.532.191 | -0,10 | 11,49 | -18.384 | 17.604.875 | |
2018-07-31 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -7.800 | 1.533.791 | -0,51 | 11,48 | -89.544 | 17.607.921 | |
2018-07-31 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -400 | 1.541.591 | -0,03 | 11,48 | -4.592 | 17.697.465 | |
2018-07-31 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -6.000 | 1.541.991 | -0,39 | 11,45 | -68.700 | 17.655.797 | |
2018-07-31 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -2.555 | 1.547.991 | -0,16 | 11,47 | -29.306 | 17.755.457 | |
2018-07-31 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -18.006 | 1.550.546 | -1,15 | 11,56 | -208.149 | 17.924.312 | |
2018-07-31 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -130.559 | 1.568.552 | -7,68 | 11,60 | -1.514.484 | 18.195.203 | |
2018-07-27 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -42.409 | 1.699.111 | -2,44 | 12,48 | -529.264 | 21.204.905 | |
2018-07-27 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -7.300 | 1.741.520 | -0,42 | 12,55 | -91.615 | 21.856.076 | |
2018-07-27 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -169.102 | 1.748.820 | -8,82 | 12,01 | -2.030.915 | 21.003.328 | |
2018-07-27 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -13.206 | 1.917.922 | -0,68 | 12,00 | -158.472 | 23.015.064 | |
2018-07-27 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -63.833 | 1.931.128 | -3,20 | 11,95 | -762.804 | 23.076.980 | |
2018-07-05 | 3 | VRAY |
ViewRay, Inc.
Common Stock |
3.991.542 | ||||||||
2018-07-05 | 3 | VRAY |
ViewRay, Inc.
Common Stock |
1.998.201 | ||||||||
2018-07-05 | 3 | VRAY |
ViewRay, Inc.
Common Stock |
3.991.542 | ||||||||
2018-07-05 | 3 | VRAY |
ViewRay, Inc.
Common Stock |
1.998.201 | ||||||||
2018-07-05 | 3 | VRAY |
ViewRay, Inc.
Common Stock |
3.991.542 | ||||||||
2018-07-05 | 3 | VRAY |
ViewRay, Inc.
Common Stock |
1.998.201 | ||||||||
2018-04-25 |
|
4 | SURF |
Surface Oncology, Inc.
Series A Preferred Stock |
C - Conversion | -4.155.773 | 0 | -100,00 | ||||
2018-04-25 |
|
4 | SURF |
Surface Oncology, Inc.
Common Stock |
C - Conversion | 1.888.986 | 1.888.986 | |||||
2018-04-05 |
|
4 | UMRX |
Unum Therapeutics Inc.
Series B Preferred Stock |
C - Conversion | -877 | 0 | -100,00 | ||||
2018-04-05 |
|
4 | UMRX |
Unum Therapeutics Inc.
Series B Preferred Stock |
C - Conversion | -73.065 | 0 | -100,00 | ||||
2018-04-05 |
|
4 | UMRX |
Unum Therapeutics Inc.
Series B Preferred Stock |
C - Conversion | -13.505 | 0 | -100,00 | ||||
2018-04-05 |
|
4 | UMRX |
Unum Therapeutics Inc.
Series A Preferred Stock |
C - Conversion | -35.614 | 0 | -100,00 | ||||
2018-04-05 |
|
4 | UMRX |
Unum Therapeutics Inc.
Series A Preferred Stock |
C - Conversion | -2.968.650 | 0 | -100,00 | ||||
2018-04-05 |
|
4 | UMRX |
Unum Therapeutics Inc.
Series A Preferred Stock |
C - Conversion | -548.702 | 0 | -100,00 | ||||
2018-04-05 |
|
4 | UMRX |
Unum Therapeutics Inc.
Common Stock |
C - Conversion | 558 | 23.240 | 2,46 | ||||
2018-04-05 |
|
4 | UMRX |
Unum Therapeutics Inc.
Common Stock |
C - Conversion | 22.682 | 22.682 | |||||
2018-04-05 |
|
4 | UMRX |
Unum Therapeutics Inc.
Common Stock |
C - Conversion | 46.534 | 1.937.235 | 2,46 | ||||
2018-04-05 |
|
4 | UMRX |
Unum Therapeutics Inc.
Common Stock |
C - Conversion | 1.890.701 | 1.890.701 | |||||
2018-04-05 |
|
4 | UMRX |
Unum Therapeutics Inc.
Common Stock |
P - Purchase | 94.052 | 452.115 | 26,27 | 12,00 | 1.128.624 | 5.425.380 | |
2018-04-05 |
|
4 | UMRX |
Unum Therapeutics Inc.
Common Stock |
C - Conversion | 8.601 | 358.063 | 2,46 | ||||
2018-04-05 |
|
4 | UMRX |
Unum Therapeutics Inc.
Common Stock |
C - Conversion | 349.462 | 349.462 | |||||
2018-01-31 |
|
4 | MNLO |
Menlo Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -821.596 | 0 | -100,00 | ||||
2018-01-31 |
|
4 | MNLO |
Menlo Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -2.194.357 | 0 | -100,00 | ||||
2018-01-31 |
|
4 | MNLO |
Menlo Therapeutics, Inc.
Common Stock |
C - Conversion | 304.576 | 1.118.054 | 37,44 | ||||
2018-01-31 |
|
4 | MNLO |
Menlo Therapeutics, Inc.
Common Stock |
C - Conversion | 813.478 | 813.478 | |||||
2017-12-22 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
7.889.515 | ||||||||
2017-12-22 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
5.997.251 | ||||||||
2017-12-22 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
4.923.209 | ||||||||
2017-12-22 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
5.639.995 | ||||||||
2017-12-22 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
7.889.515 | ||||||||
2017-12-22 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
5.997.251 | ||||||||
2017-12-22 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
4.923.209 | ||||||||
2017-12-22 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
5.639.995 | ||||||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series B-1 Convertible Preferred Stock |
C - Conversion | -1.246 | 0 | -100,00 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series B-1 Convertible Preferred Stock |
C - Conversion | -41.561 | 0 | -100,00 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series B-1 Convertible Preferred Stock |
C - Conversion | -112.590 | 0 | -100,00 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -498 | 0 | -100,00 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -16.624 | 0 | -100,00 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -45.035 | 0 | -100,00 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -24.240 | 0 | -100,00 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -808.013 | 0 | -100,00 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -2.188.869 | 0 | -100,00 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
C - Conversion | 1.246 | 33.215 | 3,90 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
C - Conversion | 498 | 31.969 | 1,58 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
C - Conversion | 24.240 | 31.471 | 335,22 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
C - Conversion | 41.561 | 1.107.257 | 3,90 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
C - Conversion | 16.624 | 1.065.696 | 1,58 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
C - Conversion | 808.013 | 1.049.072 | 335,19 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
C - Conversion | 112.590 | 2.999.521 | 3,90 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
C - Conversion | 45.035 | 2.886.931 | 1,58 | ||||
2017-12-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
C - Conversion | 2.188.869 | 2.841.896 | 335,19 | ||||
2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
2.304.345 | ||||||||
2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
1.892.377 | ||||||||
2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
1.658.549 | ||||||||
2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
2.401.319 | ||||||||
2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
2.304.345 | ||||||||
2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
1.892.377 | ||||||||
2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
1.658.549 | ||||||||
2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
2.401.319 | ||||||||
2017-11-09 |
|
4 | DMTX |
Dimension Therapeutics, Inc.
Common Stock |
U - Other | -5.057 | 0 | -100,00 | 6,00 | -30.342 | ||
2017-11-09 |
|
4 | DMTX |
Dimension Therapeutics, Inc.
Common Stock |
U - Other | -1.050.016 | 0 | -100,00 | 6,00 | -6.300.096 | ||
2017-11-09 |
|
4 | DMTX |
Dimension Therapeutics, Inc.
Common Stock |
U - Other | -3.838.249 | 0 | -100,00 | 6,00 | -23.029.494 | ||
2017-08-18 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
630.960 | ||||||||
2017-08-18 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
342.282 | ||||||||
2017-08-18 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
332.926 | ||||||||
2017-08-18 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
326.917 | ||||||||
2017-08-18 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
630.960 | ||||||||
2017-08-18 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
342.282 | ||||||||
2017-08-18 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
332.926 | ||||||||
2017-08-18 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
326.917 | ||||||||
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Series B-1 Convertible Preferred Stock |
C - Conversion | -611.606 | 0 | -100,00 | ||||
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -718.375 | 0 | -100,00 | ||||
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
C - Conversion | 611.606 | 1.329.981 | 85,14 | ||||
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
C - Conversion | 718.375 | 718.375 | |||||
2017-06-27 | 3 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
769.311 | ||||||||
2017-06-27 | 3 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
388.551 | ||||||||
2017-06-27 | 3 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
769.311 | ||||||||
2017-06-27 | 3 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
388.551 | ||||||||
2017-04-27 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -22.661 | 5.499.447 | -0,41 | 6,69 | -151.602 | 36.791.300 | |
2017-04-27 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -20 | 5.522.108 | 0,00 | 6,79 | -136 | 37.495.113 | |
2017-04-27 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -67.900 | 5.522.128 | -1,21 | 6,80 | -461.720 | 37.550.470 | |
2017-04-27 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -4.000 | 5.590.028 | -0,07 | 6,74 | -26.960 | 37.676.789 | |
2017-04-27 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -6.000 | 5.594.028 | -0,11 | 6,69 | -40.140 | 37.424.047 | |
2017-04-27 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -4.900 | 5.600.028 | -0,09 | 6,74 | -33.026 | 37.744.189 | |
2017-04-27 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -300 | 5.604.928 | -0,01 | 6,76 | -2.028 | 37.889.313 | |
2017-04-27 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.000 | 5.605.228 | -0,02 | 6,76 | -6.760 | 37.891.341 | |
2017-04-25 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -300 | 5.606.228 | -0,01 | 6,63 | -1.989 | 37.169.292 | |
2017-04-25 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -6.634 | 5.606.528 | -0,12 | 6,60 | -43.784 | 37.003.085 | |
2017-04-25 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -58.200 | 5.613.162 | -1,03 | 6,68 | -388.776 | 37.495.922 | |
2017-04-25 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -12.500 | 5.671.362 | -0,22 | 6,62 | -82.750 | 37.544.416 | |
2017-04-25 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -6.406 | 5.683.862 | -0,11 | 6,86 | -43.945 | 38.991.293 | |
2017-04-25 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -600 | 5.690.268 | -0,01 | 6,91 | -4.146 | 39.319.752 | |
2017-04-25 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -11.399 | 5.690.868 | -0,20 | 6,83 | -77.855 | 38.868.628 | |
2017-04-25 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -5.100 | 5.702.267 | -0,09 | 6,88 | -35.088 | 39.231.597 | |
2017-04-21 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -700 | 5.707.367 | -0,01 | 6,95 | -4.865 | 39.666.201 | |
2017-04-21 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -800 | 5.708.067 | -0,01 | 6,96 | -5.568 | 39.728.146 | |
2017-04-21 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.900 | 5.708.867 | -0,03 | 7,02 | -13.338 | 40.076.246 | |
2017-04-21 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -69.472 | 5.710.767 | -1,20 | 6,88 | -477.967 | 39.290.077 | |
2017-04-21 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -100 | 5.780.239 | 0,00 | 6,95 | -695 | 40.172.661 | |
2017-04-21 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -18.864 | 5.780.339 | -0,33 | 6,90 | -130.162 | 39.884.339 | |
2017-04-21 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.400 | 5.799.203 | -0,02 | 6,97 | -9.758 | 40.420.445 | |
2017-04-21 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -8.000 | 5.800.603 | -0,14 | 6,97 | -55.760 | 40.430.203 | |
2017-04-19 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -11.000 | 5.808.603 | -0,19 | 7,22 | -79.420 | 41.938.114 | |
2017-04-19 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -6.517 | 5.819.603 | -0,11 | 6,98 | -45.489 | 40.620.829 | |
2017-04-19 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.100 | 5.826.120 | -0,02 | 7,81 | -8.591 | 45.501.997 | |
2017-04-19 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -38.400 | 5.827.220 | -0,65 | 7,27 | -279.168 | 42.363.889 | |
2017-04-19 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -200 | 5.865.620 | 0,00 | 7,79 | -1.558 | 45.693.180 | |
2017-04-19 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -50.000 | 5.865.820 | -0,85 | 7,24 | -362.000 | 42.468.537 | |
2017-04-17 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -13.260 | 5.915.820 | -0,22 | 7,68 | -101.837 | 45.433.498 | |
2017-04-17 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -45.400 | 5.929.080 | -0,76 | 7,38 | -335.052 | 43.756.610 | |
2017-04-17 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -2.100 | 5.974.480 | -0,04 | 7,70 | -16.170 | 46.003.496 | |
2017-04-17 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -16.500 | 5.976.580 | -0,28 | 7,49 | -123.585 | 44.764.584 | |
2017-04-17 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -19.200 | 5.993.080 | -0,32 | 7,27 | -139.584 | 43.569.692 | |
2017-04-17 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -700 | 6.012.280 | -0,01 | 7,54 | -5.278 | 45.332.591 | |
2017-04-17 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -17.500 | 6.012.980 | -0,29 | 7,49 | -131.075 | 45.037.220 | |
2017-04-17 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -300 | 6.030.480 | 0,00 | 7,58 | -2.274 | 45.711.038 | |
2017-04-17 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -900 | 6.030.780 | -0,01 | 7,58 | -6.822 | 45.713.312 | |
2017-04-13 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -96.011 | 6.031.680 | -1,57 | 7,41 | -711.442 | 44.694.749 | |
2017-04-13 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.669 | 6.127.691 | -0,03 | 7,41 | -12.367 | 45.406.190 | |
2017-04-13 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -18.300 | 6.129.360 | -0,30 | 7,50 | -137.250 | 45.970.200 | |
2017-04-13 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.000 | 6.147.660 | -0,02 | 7,50 | -7.500 | 46.107.450 | |
2017-04-13 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -100 | 6.148.660 | 0,00 | 7,48 | -748 | 45.991.977 | |
2017-04-13 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -56.490 | 6.148.760 | -0,91 | 7,34 | -414.637 | 45.131.898 | |
2017-04-13 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -5.824 | 6.205.250 | -0,09 | 7,59 | -44.204 | 47.097.848 | |
2017-04-13 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -100 | 6.211.074 | 0,00 | 7,53 | -753 | 46.769.387 | |
2017-04-11 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -2.735 | 6.211.174 | -0,04 | 7,67 | -20.977 | 47.639.705 | |
2017-04-11 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -4.888 | 6.213.909 | -0,08 | 7,71 | -37.686 | 47.909.238 | |
2017-04-11 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -13.017 | 6.218.797 | -0,21 | 7,70 | -100.231 | 47.884.737 | |
2017-04-11 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -400 | 6.231.814 | -0,01 | 7,71 | -3.084 | 48.047.286 | |
2017-04-11 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -700 | 6.232.214 | -0,01 | 7,67 | -5.369 | 47.801.081 | |
2017-04-11 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -6.222 | 6.232.914 | -0,10 | 7,70 | -47.909 | 47.993.438 | |
2017-04-11 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -94.900 | 6.239.136 | -1,50 | 7,81 | -741.169 | 48.727.652 | |
2017-04-11 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -300 | 6.334.036 | 0,00 | 7,71 | -2.313 | 48.835.418 | |
2017-04-11 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -100 | 6.334.336 | 0,00 | 7,78 | -778 | 49.281.134 | |
2017-04-11 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -11.737 | 6.334.436 | -0,18 | 7,70 | -90.375 | 48.775.157 | |
2017-04-11 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -31.548 | 6.346.173 | -0,49 | 7,79 | -245.759 | 49.436.688 | |
2017-04-11 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -11.709 | 6.377.721 | -0,18 | 7,69 | -90.042 | 49.044.674 | |
2017-04-11 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -300 | 6.389.430 | 0,00 | 7,68 | -2.304 | 49.070.822 | |
2017-04-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -550 | 6.389.730 | -0,01 | 8,08 | -4.444 | 51.629.018 | |
2017-04-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -9.949 | 6.390.280 | -0,16 | 8,03 | -79.890 | 51.313.948 | |
2017-04-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -500 | 6.400.229 | -0,01 | 7,68 | -3.840 | 49.153.759 | |
2017-04-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -6.400 | 6.400.729 | -0,10 | 7,99 | -51.136 | 51.141.825 | |
2017-04-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.400 | 6.407.129 | -0,02 | 8,10 | -11.340 | 51.897.745 | |
2017-04-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -29.051 | 6.408.529 | -0,45 | 7,83 | -227.469 | 50.178.782 | |
2017-04-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -600 | 6.437.580 | -0,01 | 7,92 | -4.752 | 50.985.634 | |
2017-04-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -500 | 6.438.180 | -0,01 | 8,02 | -4.010 | 51.634.204 | |
2017-04-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -2.900 | 6.438.680 | -0,05 | 7,73 | -22.417 | 49.770.996 | |
2017-04-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -200 | 6.441.580 | 0,00 | 7,73 | -1.546 | 49.793.413 | |
2017-04-06 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -63.630 | 6.441.780 | -0,98 | 7,80 | -496.314 | 50.245.884 | |
2017-04-06 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -132.767 | 6.505.410 | -2,00 | 7,95 | -1.055.498 | 51.718.010 | |
2017-04-04 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -22.818 | 6.638.177 | -0,34 | 8,01 | -182.772 | 53.171.798 | |
2017-04-04 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -81.188 | 6.660.995 | -1,20 | 7,94 | -644.633 | 52.888.300 | |
2017-04-04 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -3.967 | 6.742.183 | -0,06 | 8,63 | -34.235 | 58.185.039 | |
2017-04-04 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -5.447 | 6.746.150 | -0,08 | 8,57 | -46.681 | 57.814.506 | |
2017-04-04 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -4.459 | 6.751.597 | -0,07 | 8,59 | -38.303 | 57.996.218 | |
2017-04-04 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -6.683 | 6.756.056 | -0,10 | 8,64 | -57.741 | 58.372.324 | |
2017-04-04 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -24.985 | 6.762.739 | -0,37 | 8,65 | -216.120 | 58.497.692 | |
2017-04-04 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -8.016 | 6.787.724 | -0,12 | 8,65 | -69.338 | 58.713.813 | |
2017-04-04 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -26.300 | 6.795.740 | -0,39 | 8,54 | -224.602 | 58.035.620 | |
2017-04-04 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -9.800 | 6.822.040 | -0,14 | 8,62 | -84.476 | 58.805.985 | |
2017-04-04 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -500 | 6.831.840 | -0,01 | 8,67 | -4.335 | 59.232.053 | |
2017-04-04 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -5.060 | 6.832.340 | -0,07 | 8,61 | -43.567 | 58.826.447 | |
2017-04-04 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -18.260 | 6.837.400 | -0,27 | 8,60 | -157.036 | 58.801.640 | |
2017-04-04 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -300 | 6.855.660 | 0,00 | 8,65 | -2.595 | 59.301.459 | |
2017-04-04 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -100 | 6.855.960 | 0,00 | 8,49 | -849 | 58.207.100 | |
2017-04-03 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -28.661 | 6.856.060 | -0,42 | 8,46 | -242.472 | 58.002.268 | |
2017-03-30 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
J - Other | -1.105.202 | 6.884.721 | -13,83 | ||||
2017-03-15 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -25.000 | 243.508 | -9,31 | 12,94 | -323.500 | 3.150.994 | |
2017-03-13 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -25.000 | 268.508 | -8,52 | 12,04 | -301.000 | 3.232.836 | |
2017-03-10 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -800 | 293.508 | -0,27 | 11,96 | -9.568 | 3.510.356 | |
2017-03-10 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -400 | 294.308 | -0,14 | 11,91 | -4.764 | 3.505.208 | |
2017-03-10 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -400 | 294.708 | -0,14 | 11,86 | -4.744 | 3.495.237 | |
2017-03-10 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -200 | 295.108 | -0,07 | 11,78 | -2.356 | 3.476.372 | |
2017-03-10 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -2.500 | 295.308 | -0,84 | 11,97 | -29.925 | 3.534.837 | |
2017-03-10 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -25.000 | 297.808 | -7,74 | 12,10 | -302.500 | 3.603.477 | |
2017-03-08 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -4.897 | 322.808 | -1,49 | 13,59 | -66.550 | 4.386.961 | |
2017-03-08 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -30.103 | 327.705 | -8,41 | 12,67 | -381.405 | 4.152.022 | |
2017-03-08 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -25.000 | 357.808 | -6,53 | 13,31 | -332.750 | 4.762.424 | |
2017-03-06 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -20.000 | 382.808 | -4,97 | 13,63 | -272.600 | 5.217.673 | |
2017-03-06 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -4.500 | 402.808 | -1,10 | 14,58 | -65.610 | 5.872.941 | |
2017-03-06 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -20.500 | 407.308 | -4,79 | 14,03 | -287.615 | 5.714.531 | |
2017-03-02 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -30.000 | 427.808 | -6,55 | 14,70 | -441.000 | 6.288.778 | |
2017-03-02 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -15.000 | 457.808 | -3,17 | 14,47 | -217.050 | 6.624.482 | |
2017-02-28 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -15.000 | 472.808 | -3,07 | 14,65 | -219.750 | 6.926.637 | |
2017-02-28 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -13.000 | 487.808 | -2,60 | 14,55 | -189.150 | 7.097.606 | |
2017-02-13 | 3 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
996.793 | ||||||||
2017-02-13 | 3 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
505.631 | ||||||||
2017-02-13 | 3 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
996.793 | ||||||||
2017-02-13 | 3 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
505.631 | ||||||||
2016-12-21 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
J - Other | -639.627 | 1.931.727 | -24,88 | ||||
2016-10-28 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -100 | 2.571.354 | 0,00 | 22,15 | -2.215 | 56.955.491 | |
2016-10-28 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -3.650 | 2.571.454 | -0,14 | 21,93 | -80.044 | 56.391.986 | |
2016-10-20 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
J - Other | -84.223 | 2.575.104 | -3,17 | ||||
2016-10-11 |
|
4 | EXA |
EXA CORP
Common Stock |
G - Gift | -2.105.642 | 0 | -100,00 | ||||
2016-08-31 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
J - Other | -130.571 | 2.659.327 | -4,68 | ||||
2016-08-10 |
|
4 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
S - Sale | -10.000 | 361.594 | -2,69 | 29,87 | -298.700 | 10.800.813 | |
2016-08-10 |
|
4 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
S - Sale | -84.976 | 371.594 | -18,61 | 29,86 | -2.537.383 | 11.095.797 | |
2016-08-10 |
|
4 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
S - Sale | -1.349 | 456.570 | -0,29 | 29,84 | -40.254 | 13.624.049 | |
2016-08-10 |
|
4 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
S - Sale | -1.100 | 457.919 | -0,24 | 29,92 | -32.912 | 13.700.936 | |
2016-08-10 |
|
4 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
S - Sale | -2.100 | 459.019 | -0,46 | 29,89 | -62.769 | 13.720.078 | |
2016-08-10 |
|
4 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
S - Sale | -475 | 461.119 | -0,10 | 29,89 | -14.198 | 13.782.847 | |
2016-08-08 |
|
4 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
S - Sale | -25.000 | 461.594 | -5,14 | 28,78 | -719.500 | 13.284.675 | |
2016-08-08 |
|
4 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
S - Sale | -100 | 486.594 | -0,02 | 27,95 | -2.795 | 13.600.302 | |
2016-08-08 |
|
4 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
S - Sale | -100 | 486.694 | -0,02 | 27,87 | -2.787 | 13.564.162 | |
2016-08-08 |
|
4 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
S - Sale | -200 | 486.794 | -0,04 | 27,97 | -5.594 | 13.615.628 | |
2016-08-08 |
|
4 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
S - Sale | -23.200 | 486.994 | -4,55 | 28,16 | -653.312 | 13.713.751 | |
2016-05-18 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
J - Other | -129.496 | 489.880 | -20,91 | ||||
2016-05-18 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -18.300 | 619.376 | -2,87 | 12,41 | -227.103 | 7.686.456 | |
2016-05-17 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -2.111 | 637.676 | -0,33 | 12,02 | -25.374 | 7.664.866 | |
2016-05-17 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -300 | 639.787 | -0,05 | 12,12 | -3.636 | 7.754.218 | |
2016-05-17 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -2.800 | 640.087 | -0,44 | 11,69 | -32.732 | 7.482.617 | |
2016-05-17 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -400 | 642.887 | -0,06 | 11,87 | -4.748 | 7.631.069 | |
2016-05-17 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -600 | 643.287 | -0,09 | 12,12 | -7.272 | 7.796.638 | |
2016-05-17 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -900 | 643.887 | -0,14 | 11,91 | -10.719 | 7.668.694 | |
2016-05-17 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -3.089 | 644.787 | -0,48 | 11,79 | -36.419 | 7.602.039 | |
2016-05-17 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -300 | 647.876 | -0,05 | 12,11 | -3.633 | 7.845.778 | |
2016-05-17 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -29 | 648.176 | 0,00 | 11,28 | -327 | 7.311.425 | |
2016-05-17 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 648.205 | -0,02 | 11,29 | -1.129 | 7.318.234 | |
2016-05-17 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 648.305 | -0,02 | 11,25 | -1.125 | 7.293.431 | |
2016-05-17 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -101 | 648.405 | -0,02 | 11,28 | -1.139 | 7.314.008 | |
2016-05-17 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -200 | 648.506 | -0,03 | 11,26 | -2.252 | 7.302.178 | |
2016-05-17 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -900 | 648.706 | -0,14 | 11,26 | -10.134 | 7.304.430 | |
2016-05-17 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -4.100 | 649.606 | -0,63 | 11,25 | -46.125 | 7.308.068 | |
2016-05-13 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 653.706 | -0,02 | 11,14 | -1.114 | 7.282.285 | |
2016-05-13 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 653.806 | -0,02 | 10,88 | -1.088 | 7.113.409 | |
2016-05-13 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -200 | 653.906 | -0,03 | 10,85 | -2.170 | 7.094.880 | |
2016-05-13 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -200 | 654.106 | -0,03 | 10,89 | -2.178 | 7.123.214 | |
2016-05-13 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -400 | 654.306 | -0,06 | 10,93 | -4.372 | 7.151.565 | |
2016-05-13 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -500 | 654.706 | -0,08 | 10,85 | -5.425 | 7.103.560 | |
2016-05-13 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -1.711 | 655.206 | -0,26 | 10,86 | -18.581 | 7.115.537 | |
2016-05-13 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -3.500 | 656.917 | -0,53 | 10,83 | -37.905 | 7.114.411 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 660.417 | -0,02 | 11,22 | -1.122 | 7.409.879 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -200 | 660.517 | -0,03 | 10,30 | -2.060 | 6.803.325 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -500 | 660.717 | -0,08 | 10,28 | -5.140 | 6.792.171 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -700 | 661.217 | -0,11 | 10,70 | -7.490 | 7.075.022 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -743 | 661.917 | -0,11 | 10,97 | -8.151 | 7.261.229 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -900 | 662.660 | -0,14 | 10,38 | -9.342 | 6.878.411 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -1.300 | 663.560 | -0,20 | 10,58 | -13.754 | 7.020.465 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -2.200 | 664.860 | -0,33 | 10,98 | -24.156 | 7.300.163 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -3.400 | 667.060 | -0,51 | 10,53 | -35.802 | 7.024.142 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -4.146 | 670.460 | -0,61 | 10,40 | -43.118 | 6.972.784 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -200 | 674.606 | -0,03 | 10,11 | -2.022 | 6.820.267 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -300 | 674.806 | -0,04 | 10,14 | -3.042 | 6.842.533 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -600 | 675.106 | -0,09 | 10,12 | -6.072 | 6.832.073 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -700 | 675.706 | -0,10 | 10,06 | -7.042 | 6.797.602 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -800 | 676.406 | -0,12 | 10,20 | -8.160 | 6.899.341 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -2.400 | 677.206 | -0,35 | 10,13 | -24.312 | 6.860.097 | |
2016-05-12 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -5.943 | 679.606 | -0,87 | 10,04 | -59.668 | 6.823.244 | |
2016-05-10 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -200 | 685.549 | -0,03 | 9,90 | -1.980 | 6.786.935 | |
2016-05-10 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -200 | 685.749 | -0,03 | 9,89 | -1.978 | 6.782.058 | |
2016-05-10 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -200 | 685.949 | -0,03 | 9,88 | -1.976 | 6.777.176 | |
2016-05-10 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -300 | 686.149 | -0,04 | 9,94 | -2.982 | 6.820.321 | |
2016-05-10 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -400 | 686.449 | -0,06 | 9,89 | -3.956 | 6.788.981 | |
2016-05-10 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -4.431 | 686.849 | -0,64 | 9,94 | -44.044 | 6.827.279 | |
2016-05-10 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 691.280 | -0,01 | 10,05 | -1.005 | 6.947.364 | |
2016-05-10 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 691.380 | -0,01 | 9,94 | -994 | 6.872.317 | |
2016-05-10 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -200 | 691.480 | -0,03 | 9,89 | -1.978 | 6.838.737 | |
2016-05-10 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -300 | 691.680 | -0,04 | 9,90 | -2.970 | 6.847.632 | |
2016-05-10 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -500 | 691.980 | -0,07 | 9,99 | -4.995 | 6.912.880 | |
2016-05-10 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -562 | 692.480 | -0,08 | 9,95 | -5.592 | 6.890.176 | |
2016-05-10 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -600 | 693.042 | -0,09 | 9,98 | -5.988 | 6.916.559 | |
2016-05-10 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -600 | 693.642 | -0,09 | 9,90 | -5.940 | 6.867.056 | |
2016-05-10 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -900 | 694.242 | -0,13 | 10,03 | -9.027 | 6.963.247 | |
2016-05-10 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -977 | 695.142 | -0,14 | 9,91 | -9.682 | 6.888.857 | |
2016-05-06 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 696.119 | -0,01 | 10,42 | -1.042 | 7.253.560 | |
2016-05-06 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 696.219 | -0,01 | 10,45 | -1.045 | 7.275.489 | |
2016-05-06 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 696.319 | -0,01 | 10,51 | -1.051 | 7.318.313 | |
2016-05-06 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 696.419 | -0,01 | 10,43 | -1.043 | 7.263.650 | |
2016-05-06 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -300 | 696.519 | -0,04 | 10,52 | -3.156 | 7.327.380 | |
2016-05-06 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -1.196 | 696.819 | -0,17 | 10,52 | -12.582 | 7.330.536 | |
2016-05-04 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -300 | 698.015 | -0,04 | 10,81 | -3.243 | 7.545.542 | |
2016-05-04 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -450 | 698.315 | -0,06 | 10,73 | -4.828 | 7.492.920 | |
2016-05-04 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -1.000 | 698.765 | -0,14 | 10,76 | -10.760 | 7.518.711 | |
2016-05-04 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -1.900 | 699.765 | -0,27 | 10,73 | -20.387 | 7.508.478 | |
2016-05-04 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 701.665 | -0,01 | 10,89 | -1.089 | 7.641.132 | |
2016-05-04 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 701.765 | -0,01 | 10,90 | -1.090 | 7.649.238 | |
2016-05-04 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -160 | 701.865 | -0,02 | 10,89 | -1.742 | 7.643.310 | |
2016-05-04 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -400 | 702.025 | -0,06 | 10,87 | -4.348 | 7.631.012 | |
2016-05-04 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -600 | 702.425 | -0,09 | 10,89 | -6.534 | 7.649.408 | |
2016-05-04 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -1.036 | 703.025 | -0,15 | 10,66 | -11.044 | 7.494.246 | |
2016-05-03 |
|
4 | DMTX |
Dimension Therapeutics, Inc.
Common Stock |
J - Other | -2.106.784 | 4.893.322 | -30,10 | ||||
2016-05-02 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 704.061 | -0,01 | 11,38 | -1.138 | 8.012.214 | |
2016-05-02 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -4.623 | 704.161 | -0,65 | 10,79 | -49.882 | 7.597.897 | |
2016-04-29 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 708.784 | -0,01 | 11,26 | -1.126 | 7.980.908 | |
2016-04-29 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 708.884 | -0,01 | 11,29 | -1.129 | 8.003.300 | |
2016-04-29 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 708.984 | -0,01 | 11,34 | -1.134 | 8.039.879 | |
2016-04-29 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -100 | 709.084 | -0,01 | 11,23 | -1.123 | 7.963.013 | |
2016-04-29 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -300 | 709.184 | -0,04 | 11,26 | -3.378 | 7.985.412 | |
2016-04-29 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -1.900 | 709.484 | -0,27 | 11,28 | -21.432 | 8.002.980 | |
2016-04-29 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -2.318 | 711.384 | -0,32 | 11,52 | -26.703 | 8.195.144 | |
2016-04-29 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -200 | 713.702 | -0,03 | 11,20 | -2.240 | 7.993.462 | |
2016-04-29 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -600 | 713.902 | -0,08 | 11,14 | -6.684 | 7.952.868 | |
2016-04-29 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -2.066 | 714.502 | -0,29 | 11,20 | -23.139 | 8.002.422 | |
2016-04-29 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -25.412 | 716.568 | -3,42 | 11,20 | -284.614 | 8.025.562 | |
2016-04-27 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -5.300 | 741.980 | -0,71 | 11,12 | -58.936 | 8.250.818 | |
2016-04-27 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -3.888 | 747.280 | -0,52 | 11,29 | -43.896 | 8.436.791 | |
2016-04-25 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -17.358 | 751.168 | -2,26 | 11,30 | -196.145 | 8.488.198 | |
2016-04-25 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -3.200 | 768.526 | -0,41 | 11,28 | -36.096 | 8.668.973 | |
2016-04-21 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
J - Other | -1.014.381 | 2.789.898 | -26,66 | ||||
2016-04-21 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -4.200 | 771.726 | -0,54 | 11,42 | -47.964 | 8.813.111 | |
2016-04-21 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -8.989 | 775.926 | -1,15 | 11,77 | -105.801 | 9.132.649 | |
2016-04-19 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -9.600 | 784.915 | -1,21 | 11,94 | -114.624 | 9.371.885 | |
2016-04-19 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -9.300 | 794.515 | -1,16 | 11,56 | -107.508 | 9.184.593 | |
2016-04-15 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -4.734 | 803.815 | -0,59 | 11,57 | -54.772 | 9.300.140 | |
2016-04-15 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -20.000 | 808.549 | -2,41 | 11,44 | -228.800 | 9.249.801 | |
2016-04-15 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
S - Sale | -2.302 | 828.549 | -0,28 | 11,44 | -26.335 | 9.478.601 | |
2016-03-30 | 3 | VRAY |
ViewRay, Inc.
Common Stock |
15.979.846 | ||||||||
2016-03-30 | 3 | VRAY |
ViewRay, Inc.
Common Stock |
15.979.846 | ||||||||
2016-03-18 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
J - Other | -254.965 | 830.851 | -23,48 | ||||
2016-02-18 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Series B Convertible Preferred Stock |
C - Conversion | -1.987.782 | 0 | -100,00 | ||||
2016-02-18 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Series A Convertible Preferred Stock |
C - Conversion | -10.000.000 | 0 | -100,00 | ||||
2016-02-18 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
P - Purchase | 375.000 | 1.877.812 | 24,95 | 8,00 | 3.000.000 | 15.022.496 | |
2016-02-18 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
C - Conversion | 183.880 | 1.502.812 | 13,94 | ||||
2016-02-18 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
C - Conversion | 925.051 | 1.318.932 | 234,86 | ||||
2015-11-30 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -55.419 | 264.898 | -17,30 | 21,97 | -1.217.555 | 5.819.809 | |
2015-11-30 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -2.400 | 320.317 | -0,74 | 21,86 | -52.464 | 7.002.130 | |
2015-11-30 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -174.096 | 322.717 | -35,04 | 21,48 | -3.739.582 | 6.931.961 | |
2015-11-30 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -55.500 | 496.813 | -10,05 | 20,97 | -1.163.835 | 10.418.169 | |
2015-11-25 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -161.271 | 552.313 | -22,60 | 20,14 | -3.247.998 | 11.123.584 | |
2015-11-23 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -61.600 | 713.584 | -7,95 | 20,22 | -1.245.552 | 14.428.668 | |
2015-11-23 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -23.700 | 775.184 | -2,97 | 20,05 | -475.185 | 15.542.439 | |
2015-11-23 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -81.272 | 798.884 | -9,23 | 20,17 | -1.639.256 | 16.113.490 | |
2015-11-23 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -23.000 | 880.156 | -2,55 | 20,02 | -460.460 | 17.620.723 | |
2015-11-20 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -131.044 | 903.156 | -12,67 | 19,79 | -2.593.361 | 17.873.457 | |
2015-11-20 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -24.850 | 1.034.200 | -2,35 | 19,93 | -495.260 | 20.611.606 | |
2015-11-20 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -76.024 | 1.059.050 | -6,70 | 19,69 | -1.496.913 | 20.852.694 | |
2015-11-20 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -100 | 1.135.074 | -0,01 | 20,19 | -2.019 | 22.917.144 | |
2015-11-20 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -5.200 | 1.135.174 | -0,46 | 19,41 | -100.932 | 22.033.727 | |
2015-11-19 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -464 | 1.140.374 | -0,04 | 20,20 | -9.373 | 23.035.555 | |
2015-11-19 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -8.509 | 1.140.838 | -0,74 | 21,07 | -179.285 | 24.037.457 | |
2015-11-19 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -14.717 | 1.149.347 | -1,26 | 20,31 | -298.902 | 23.343.238 | |
2015-11-19 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -3.800 | 1.164.064 | -0,33 | 20,70 | -78.660 | 24.096.125 | |
2015-11-19 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
G - Gift | -733 | 1.167.864 | -0,06 | ||||
2015-11-18 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -2.779 | 1.168.597 | -0,24 | 20,77 | -57.720 | 24.271.760 | |
2015-11-18 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -300 | 1.171.376 | -0,03 | 22,02 | -6.606 | 25.793.700 | |
2015-11-18 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -1.820 | 1.171.676 | -0,16 | 21,41 | -38.966 | 25.085.583 | |
2015-11-18 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
S - Sale | -23.785 | 1.173.496 | -1,99 | 20,78 | -494.252 | 24.385.247 | |
2015-11-17 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
G - Gift | -25.955 | 1.197.281 | -2,12 | ||||
2015-11-17 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
G - Gift | -4.567 | 1.223.236 | -0,37 | ||||
2015-11-17 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
G - Gift | -68.628 | 1.227.803 | -5,29 | ||||
2015-11-17 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
J - Other | -1.204.280 | 1.296.431 | -48,16 | ||||
2015-10-29 |
|
4 | DMTX |
Dimension Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | 4.761.313 | 0 | -100,00 | ||||
2015-10-29 |
|
4 | DMTX |
Dimension Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | 15.000.000 | 0 | -100,00 | ||||
2015-10-29 |
|
4 | DMTX |
Dimension Therapeutics, Inc.
Common Stock |
C - Conversion | 1.628.914 | 7.000.106 | 30,33 | ||||
2015-10-29 |
|
4 | DMTX |
Dimension Therapeutics, Inc.
Common Stock |
C - Conversion | 5.131.713 | 5.371.192 | 2.142,87 | ||||
2015-10-29 | 3 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
619.672 | ||||||||
2015-10-29 | 3 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
910.382 | ||||||||
2015-10-29 | 3 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
510.722 | ||||||||
2015-10-29 | 3 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
619.672 | ||||||||
2015-10-29 | 3 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
910.382 | ||||||||
2015-10-29 | 3 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
510.722 | ||||||||
2015-10-21 | 3 | DMTX |
Dimension Therapeutics, Inc.
Common Stock |
478.958 | ||||||||
2015-10-21 | 3 | DMTX |
Dimension Therapeutics, Inc.
Common Stock |
478.958 | ||||||||
2015-10-14 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | 1.496.764 | 0 | -100,00 | ||||
2015-10-14 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | 1.818.182 | 0 | -100,00 | ||||
2015-10-14 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | 8.652.500 | 0 | -100,00 | ||||
2015-10-14 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
P - Purchase | 335.455 | 3.804.279 | 9,67 | 11,00 | 3.690.005 | 41.847.069 | |
2015-10-14 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
C - Conversion | 433.844 | 3.468.824 | 14,29 | ||||
2015-10-14 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
C - Conversion | 527.009 | 3.034.980 | 21,01 | ||||
2015-10-14 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
C - Conversion | 2.507.971 | 2.507.971 | |||||
2015-09-25 | 3 | RGNX |
REGENXBIO Inc.
Common Stock |
2.171.632 | ||||||||
2015-09-25 | 3 | RGNX |
REGENXBIO Inc.
Common Stock |
2.171.632 | ||||||||
2015-08-21 | 3 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
619.672 | ||||||||
2015-08-21 | 3 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
910.382 | ||||||||
2015-08-21 | 3 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
510.722 | ||||||||
2015-08-21 | 3 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
619.672 | ||||||||
2015-08-21 | 3 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
910.382 | ||||||||
2015-08-21 | 3 | CHRS |
Coherus BioSciences, Inc.
Common Stock |
510.722 | ||||||||
2015-05-07 |
|
4 | BPMC |
Blueprint Medicines Corp
Series C Convertible Preferred Stock |
C - Conversion | 483.092 | 0 | -100,00 | ||||
2015-05-07 |
|
4 | BPMC |
Blueprint Medicines Corp
Series B Convertible Preferred Stock |
C - Conversion | 2.583.333 | 0 | -100,00 | ||||
2015-05-07 |
|
4 | BPMC |
Blueprint Medicines Corp
Series A Convertible Preferred Stock |
C - Conversion | 10.000.000 | 0 | -100,00 | ||||
2015-05-07 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
P - Purchase | 125.000 | 2.500.711 | 5,26 | 18,00 | 2.250.000 | 45.012.798 | |
2015-05-07 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
C - Conversion | 87.834 | 2.375.711 | 3,84 | ||||
2015-05-07 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
C - Conversion | 469.696 | 2.287.877 | 25,83 | ||||
2015-05-07 |
|
4 | BPMC |
Blueprint Medicines Corp
Common Stock |
C - Conversion | 1.818.181 | 1.818.181 | |||||
2015-03-09 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
G - Gift | -671.912 | 0 | -100,00 | ||||
2015-02-06 | 3 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
1.343.824 | ||||||||
2015-02-06 | 3 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
1.343.824 | ||||||||
2014-08-05 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Common Stock |
J - Other | -1.802.246 | 1.457.994 | -55,28 | ||||
2014-07-03 |
|
4 | GNRC |
GENERAC HOLDINGS INC.
Common Stock |
P - Purchase | 27.168 | 763.071 | 3,69 | 47,04 | 1.277.983 | 35.894.860 | |
2014-07-03 | 3 | GNRC |
GENERAC HOLDINGS INC.
Common Stock |
1.471.006 | ||||||||
2014-07-03 | 3 | GNRC |
GENERAC HOLDINGS INC.
Common Stock |
736.703 | ||||||||
2014-07-03 | 3 | GNRC |
GENERAC HOLDINGS INC.
Common Stock |
1.471.006 | ||||||||
2014-07-03 | 3 | GNRC |
GENERAC HOLDINGS INC.
Common Stock |
736.703 | ||||||||
2014-05-29 |
|
4 | GTAT |
GT Advanced Technologies Inc.
Common Stock |
S - Sale | -464.771 | 1.078.006 | -30,13 | 15,98 | -7.425.228 | 17.222.332 | |
2014-04-09 | 3 | GTAT |
GT Advanced Technologies Inc.
Common Stock |
3.085.554 | ||||||||
2014-04-09 | 3 | GTAT |
GT Advanced Technologies Inc.
Common Stock |
3.085.554 | ||||||||
2014-02-05 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Common Stock |
P - Purchase | 175.000 | 3.260.240 | 5,67 | 21,00 | 3.675.000 | 68.465.040 | |
2014-02-05 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Series B Convertible Preferred Stock |
C - Conversion | -541.634 | 0 | -100,00 | ||||
2014-02-05 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Series A Convertible Preferred Stock |
C - Conversion | -9.129.063 | 0 | -100,00 | ||||
2014-02-05 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Common Stock |
C - Conversion | 172.797 | 3.085.240 | 5,93 | ||||
2014-02-05 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Common Stock |
C - Conversion | 2.912.443 | 2.912.443 | |||||
2013-11-25 | 3 | GTAT |
GT Advanced Technologies Inc.
Common Stock |
1.305.927 | ||||||||
2013-08-30 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | -526.531 | 2.619.036 | -16,74 | 27,86 | -14.666.784 | 72.954.557 | |
2013-08-30 |
|
4 | XOOM |
XOOM Corp
Common Stock |
S - Sale | -224 | 3.145.567 | -0,01 | 27,86 | -6.240 | 87.621.342 | |
2013-08-27 |
|
4 | XOOM |
XOOM Corp
Common Stock |
S - Sale | -127 | 3.145.791 | 0,00 | 28,74 | -3.650 | 90.405.944 | |
2013-08-22 |
|
4 | XOOM |
XOOM Corp
Common Stock |
S - Sale | -127 | 3.145.918 | 0,00 | 29,06 | -3.690 | 91.413.456 | |
2013-08-22 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | -38.227 | 3.146.045 | -1,20 | 28,18 | -1.077.237 | 88.655.548 | |
2013-07-23 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -354 | 2.221 | -13,75 | 11,96 | -4.234 | 26.564 | |
2013-07-23 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -52.262 | 327.234 | -13,77 | 11,96 | -625.069 | 3.913.817 | |
2013-07-23 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -714 | 2.575 | -21,71 | 12,06 | -8.609 | 31.046 | |
2013-07-23 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -105.428 | 379.496 | -21,74 | 12,06 | -1.271.124 | 4.575.507 | |
2013-07-18 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -177 | 3.289 | -5,11 | 11,85 | -2.097 | 38.968 | |
2013-07-18 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -26.167 | 484.924 | -5,12 | 11,85 | -310.029 | 5.745.428 | |
2013-07-18 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -1.529 | 3.466 | -30,61 | 11,66 | -17.823 | 40.403 | |
2013-07-18 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -225.702 | 511.091 | -30,63 | 11,66 | -2.630.986 | 5.957.737 | |
2013-07-18 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -381 | 4.995 | -7,09 | 10,65 | -4.057 | 53.186 | |
2013-07-18 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -56.271 | 736.793 | -7,10 | 10,65 | -599.162 | 7.845.225 | |
2013-07-15 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -326 | 5.376 | -5,72 | 10,93 | -3.564 | 58.765 | |
2013-07-15 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -48.146 | 793.064 | -5,72 | 10,93 | -526.284 | 8.668.983 | |
2013-07-15 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -347 | 5.702 | -5,74 | 10,56 | -3.663 | 60.186 | |
2013-07-15 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -51.181 | 841.210 | -5,74 | 10,56 | -540.231 | 8.879.224 | |
2013-07-15 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -414 | 6.049 | -6,41 | 10,89 | -4.507 | 65.856 | |
2013-07-15 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -61.117 | 892.391 | -6,41 | 10,89 | -665.387 | 9.715.550 | |
2013-07-09 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -288 | 6.463 | -4,27 | 9,98 | -2.873 | 64.483 | |
2013-07-09 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -42.537 | 953.508 | -4,27 | 9,98 | -424.400 | 9.513.340 | |
2013-07-09 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -294 | 6.751 | -4,17 | 10,17 | -2.991 | 68.675 | |
2013-07-09 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -43.346 | 996.045 | -4,17 | 10,17 | -440.937 | 10.132.268 | |
2013-07-09 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -405 | 7.045 | -5,44 | 9,92 | -4.018 | 69.891 | |
2013-07-09 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -59.729 | 1.039.391 | -5,43 | 9,92 | -592.548 | 10.311.382 | |
2013-07-03 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -305 | 7.450 | -3,93 | 9,96 | -3.039 | 74.228 | |
2013-07-03 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -45.034 | 1.099.120 | -3,94 | 9,96 | -448.696 | 10.951.082 | |
2013-07-03 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -612 | 7.755 | -7,31 | 9,90 | -6.061 | 76.800 | |
2013-07-03 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -90.352 | 1.144.154 | -7,32 | 9,90 | -894.783 | 11.330.900 | |
2013-07-03 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -1.545 | 8.367 | -15,59 | 9,99 | -15.428 | 83.551 | |
2013-07-03 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -227.931 | 1.234.506 | -15,59 | 9,99 | -2.276.073 | 12.327.530 | |
2013-06-26 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -337 | 9.912 | -3,29 | 12,00 | -4.044 | 118.944 | |
2013-06-26 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -49.663 | 1.462.437 | -3,28 | 12,00 | -595.956 | 17.549.244 | |
2013-06-21 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -673 | 10.249 | -6,16 | 12,14 | -8.167 | 124.372 | |
2013-06-21 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -99.327 | 1.512.100 | -6,16 | 12,14 | -1.205.333 | 18.349.334 | |
2013-06-21 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -290 | 10.922 | -2,59 | 12,47 | -3.616 | 136.204 | |
2013-06-21 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -42.798 | 1.611.427 | -2,59 | 12,47 | -533.717 | 20.095.462 | |
2013-06-13 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -415 | 11.212 | -3,57 | 13,00 | -5.396 | 145.796 | |
2013-06-13 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -61.248 | 1.654.225 | -3,57 | 13,00 | -796.444 | 21.510.880 | |
2013-06-13 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -162 | 11.627 | -1,37 | 13,01 | -2.107 | 151.232 | |
2013-06-13 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -23.933 | 1.715.473 | -1,38 | 13,01 | -311.297 | 22.313.157 | |
2013-06-06 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -673 | 11.789 | -5,40 | 12,77 | -8.596 | 150.570 | |
2013-06-06 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -99.327 | 1.739.406 | -5,40 | 12,77 | -1.268.614 | 22.215.867 | |
2013-06-06 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -206 | 12.462 | -1,63 | 13,13 | -2.704 | 163.579 | |
2013-06-06 |
|
4 | INSM |
INSMED INC
Common Stock |
S - Sale | -30.351 | 1.838.733 | -1,62 | 13,13 | -398.393 | 24.135.577 | |
2013-05-06 | 3 | XOOM |
XOOM Corp
Common Stock |
3.126.701 | ||||||||
2013-05-06 | 3 | XOOM |
XOOM Corp
Common Stock |
57.571 | ||||||||
2013-04-02 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -158.068 | 837.736 | -15,87 | 18,40 | -2.908.530 | 15.414.761 | |
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series C Convertible Preferred Stock |
C - Conversion | -183.283 | 0 | -100,00 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series B Convertible Preferred Stock |
C - Conversion | -76.891 | 0 | -100,00 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series A-2 Convertible Preferred Stock |
C - Conversion | -18.351 | 0 | -100,00 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series A-1 Convertible Preferred Stock |
C - Conversion | -14.069 | 0 | -100,00 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series C Convertible Preferred Stock |
C - Conversion | -27.043.477 | 0 | -100,00 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series B Convertible Preferred Stock |
C - Conversion | -11.345.154 | 0 | -100,00 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series A-2 Convertible Preferred Stock |
C - Conversion | -2.707.735 | 0 | -100,00 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series A-1 Convertible Preferred Stock |
C - Conversion | -2.075.931 | 0 | -100,00 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 10.089 | 2.141.645 | 0,47 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 1.488.699 | 2.131.556 | 231,58 | ||||
2013-03-25 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -240.100 | 995.804 | -19,43 | ||||
2013-03-22 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4.329 | 642.857 | 0,68 | 7,00 | 30.303 | 4.499.999 | |
2013-03-22 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 638.528 | 638.528 | 7,00 | 4.469.696 | 4.469.696 | ||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series F Convertible Preferred Stock |
C - Conversion | -16.423 | 0 | -100,00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series E Convertible Preferred Stock |
C - Conversion | -16.428 | 0 | -100,00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series D Convertible Preferred Stock |
C - Conversion | -197.436 | 0 | -100,00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series F Convertible Preferred Stock |
C - Conversion | -891.925 | 0 | -100,00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series E Convertible Preferred Stock |
C - Conversion | -892.184 | 0 | -100,00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series D Convertible Preferred Stock |
C - Conversion | -10.722.699 | 0 | -100,00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Common Stock |
C - Conversion | 57.571 | 57.571 | |||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Common Stock |
C - Conversion | 3.126.701 | 3.126.701 | |||||
2012-11-02 | 3 | INSM |
INSMED INC
Common Stock |
1.869.084 | ||||||||
2012-11-02 | 3 | INSM |
INSMED INC
Common Stock |
12.668 | ||||||||
2012-10-15 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -35.153 | 1.235.904 | -2,77 | 13,13 | -461.541 | 16.226.802 | |
2012-10-15 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -118.220 | 1.271.057 | -8,51 | 13,37 | -1.580.743 | 16.995.557 | |
2012-10-15 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -59.502 | 1.389.277 | -4,11 | 13,08 | -778.310 | 18.172.299 | |
2012-10-09 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -5.878 | 1.448.779 | -0,40 | 13,00 | -76.432 | 18.838.618 | |
2012-10-09 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -12.727 | 1.454.657 | -0,87 | 13,02 | -165.746 | 18.944.289 | |
2012-10-09 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -700 | 1.467.384 | -0,05 | 13,00 | -9.100 | 19.075.992 | |
2012-10-03 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -6.300 | 1.468.084 | -0,43 | 13,00 | -81.900 | 19.085.092 | |
2012-10-03 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -2.100 | 1.474.384 | -0,14 | 13,02 | -27.333 | 19.190.140 | |
2012-09-28 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -43.622 | 1.476.484 | -2,87 | 13,24 | -577.342 | 19.541.413 | |
2012-09-28 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -51.073 | 1.520.106 | -3,25 | 13,20 | -674.363 | 20.071.328 | |
2012-09-25 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -36.056 | 1.571.179 | -2,24 | 13,88 | -500.634 | 21.815.663 | |
2012-09-25 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -80.409 | 1.607.235 | -4,76 | 14,09 | -1.133.011 | 22.646.905 | |
2012-09-25 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -119.221 | 1.806.865 | -6,19 | 14,89 | -1.775.070 | 26.902.232 | |
2012-09-20 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -53.342 | 1.806.865 | -2,87 | 13,75 | -733.613 | 24.849.814 | |
2012-09-20 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -55.878 | 1.860.207 | -2,92 | 13,34 | -745.379 | 24.814.045 | |
2012-09-20 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -49.113 | 1.916.085 | -2,50 | 13,53 | -664.317 | 25.917.541 | |
2012-09-17 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -39.337 | 1.965.198 | -1,96 | 13,22 | -519.909 | 25.973.629 | |
2012-09-17 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -84.925 | 2.004.535 | -4,06 | 13,14 | -1.115.719 | 26.334.979 | |
2012-09-17 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -29.514 | 2.089.460 | -1,39 | 13,06 | -385.491 | 27.291.064 | |
2012-09-04 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -24.100 | 2.118.974 | -1,12 | 13,16 | -317.120 | 27.882.519 | |
2012-08-01 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -5.345 | 2.143.074 | -0,25 | 13,09 | -69.971 | 28.054.767 | |
2012-08-01 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -2.100 | 2.148.419 | -0,10 | 13,26 | -27.839 | 28.480.946 | |
2012-07-30 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -41.419 | 2.150.519 | -1,89 | 13,38 | -554.012 | 28.764.912 | |
2012-07-30 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -17.261 | 2.191.938 | -0,78 | 13,07 | -225.624 | 28.651.479 | |
2012-07-30 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -200 | 2.209.199 | -0,01 | 13,00 | -2.600 | 28.719.587 | |
2012-07-24 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -6.900 | 2.209.399 | -0,31 | 13,01 | -89.743 | 28.736.106 | |
2012-07-24 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -16.040 | 2.216.299 | -0,72 | 13,08 | -209.882 | 29.000.051 | |
2012-07-20 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -47.252 | 2.232.363 | -2,07 | 13,35 | -630.828 | 29.802.716 | |
2012-07-20 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -18.060 | 2.279.615 | -0,79 | 13,40 | -242.029 | 30.550.032 | |
2012-07-20 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -7.903 | 2.297.675 | -0,34 | 13,63 | -107.716 | 31.316.621 | |
2012-07-16 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -14.708 | 2.305.578 | -0,63 | 13,80 | -202.956 | 31.814.671 | |
2012-07-16 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -20.005 | 2.320.286 | -0,85 | 13,78 | -275.673 | 31.974.005 | |
2012-07-16 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -600 | 2.340.291 | -0,03 | 13,33 | -7.999 | 31.199.823 | |
2012-07-11 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -4.900 | 2.340.891 | -0,21 | 13,86 | -67.934 | 32.454.347 | |
2012-07-11 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -14.055 | 2.345.791 | -0,60 | 13,77 | -193.497 | 32.294.739 | |
2012-07-06 |
|
4 | EXA |
EXA CORP
Series I Convertible Preferred Stock |
C - Conversion | -482.118 | 0 | -100,00 | ||||
2012-07-06 |
|
4 | EXA |
EXA CORP
Series C Convertible Preferred Stock |
C - Conversion | -970.233 | 0 | -100,00 | ||||
2012-07-06 |
|
4 | EXA |
EXA CORP
Series B Convertible Preferred Stock |
C - Conversion | -1.184.320 | 0 | -100,00 | ||||
2012-07-06 |
|
4 | EXA |
EXA CORP
Series I Convertible Preferred Stock |
C - Conversion | -2.063.699 | 0 | -100,00 | ||||
2012-07-06 |
|
4 | EXA |
EXA CORP
Series H Convertible Preferred Stock |
C - Conversion | -14.697.131 | 0 | -100,00 | ||||
2012-07-06 |
|
4 | EXA |
EXA CORP
Series G Convertible Preferred Stock |
C - Conversion | -2.671.246 | 0 | -100,00 | ||||
2012-07-06 |
|
4 | EXA |
EXA CORP
Series C Convertible Preferred Stock |
C - Conversion | -970.223 | 0 | -100,00 | ||||
2012-07-06 |
|
4 | EXA |
EXA CORP
Series B Convertible Preferred Stock |
C - Conversion | -1.203.822 | 0 | -100,00 | ||||
2012-07-06 |
|
4 | EXA |
EXA CORP
Series A Convertible Preferred Stock |
C - Conversion | -1.858.800 | 0 | -100,00 | ||||
2012-07-06 |
|
4 | EXA |
EXA CORP
Series H Convertible Preferred Stock |
C - Conversion | -937.252 | 0 | -100,00 | ||||
2012-07-06 |
|
4 | EXA |
EXA CORP
Series G Convertible Preferred Stock |
C - Conversion | -103.315 | 0 | -100,00 | ||||
2012-07-06 |
|
4 | EXA |
EXA CORP
Common Stock |
S - Sale | -405.641 | 0 | -100,00 | 9,30 | -3.772.461 | ||
2012-07-06 |
|
4 | EXA |
EXA CORP
Common Stock |
S - Sale | -1.514.607 | 2.105.640 | -41,84 | 9,30 | -14.085.845 | 19.582.452 | |
2012-07-06 |
|
4 | EXA |
EXA CORP
Common Stock |
S - Sale | -160.086 | 0 | -100,00 | 9,30 | -1.488.800 | ||
2012-07-06 |
|
4 | EXA |
EXA CORP
Common Stock |
C - Conversion | 405.641 | 405.641 | |||||
2012-07-06 |
|
4 | EXA |
EXA CORP
Common Stock |
C - Conversion | 3.609.986 | 3.620.247 | 35.181,62 | ||||
2012-07-06 |
|
4 | EXA |
EXA CORP
Common Stock |
C - Conversion | 160.086 | 160.086 | |||||
2012-07-06 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -18.065 | 2.359.846 | -0,76 | 13,90 | -251.125 | 32.804.691 | |
2012-07-06 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -16.960 | 2.377.911 | -0,71 | 14,00 | -237.423 | 33.288.376 | |
2012-07-06 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -9.392 | 2.394.871 | -0,39 | 13,96 | -131.107 | 33.430.962 | |
2012-07-02 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -14.700 | 2.404.263 | -0,61 | 13,92 | -204.624 | 33.467.341 | |
2012-07-02 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -36.600 | 2.418.963 | -1,49 | 13,77 | -503.982 | 33.309.121 | |
2012-07-02 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
S - Sale | -5.274 | 2.455.563 | -0,21 | 13,94 | -73.520 | 34.230.548 | |
2012-06-28 | 3 | EXA |
EXA CORP
Common Stock |
10.261 | ||||||||
2012-03-16 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
G - Gift | -1.225.178 | 2.460.837 | -33,24 |